Key Points
- Casdin Partners Master Fund, L bought 350,000 shares of Standard BioTools on Nov. 19 at $1.28 and, across multiple recent transactions (including buys on Nov. 7–20 and Sept. 9), acquired roughly $4.0M of stock, bringing its holdings to about 63.6 million shares (~$81.4M), a 0.55% increase in ownership.
- Standard BioTools (LAB) is trading around $1.28–$1.30 with a market cap near $498M, while analysts have grown negative—the consensus rating is "Reduce" with an average target of $1.35 and several recent downgrades and sell reiterations.
Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Casdin Partners Master Fund, L bought 275,000 shares of the business's stock in a transaction on Tuesday, November 18th. The stock was purchased at an average cost of $1.23 per share, with a total value of $338,250.00. Following the purchase, the director owned 63,250,000 shares of the company's stock, valued at $77,797,500. This represents a 0.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Casdin Partners Master Fund, L also recently made the following trade(s):
- On Thursday, November 20th, Casdin Partners Master Fund, L acquired 450,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.30 per share, with a total value of $585,000.00.
- On Wednesday, November 19th, Casdin Partners Master Fund, L bought 350,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.28 per share, for a total transaction of $448,000.00.
- On Monday, November 17th, Casdin Partners Master Fund, L purchased 225,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.22 per share, with a total value of $274,500.00.
- On Friday, November 14th, Casdin Partners Master Fund, L acquired 250,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.24 per share, for a total transaction of $310,000.00.
- On Thursday, November 13th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.20 per share, with a total value of $540,000.00.
- On Wednesday, November 12th, Casdin Partners Master Fund, L bought 375,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.19 per share, with a total value of $446,250.00.
- On Tuesday, November 11th, Casdin Partners Master Fund, L bought 300,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $360,000.00.
- On Monday, November 10th, Casdin Partners Master Fund, L purchased 275,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.17 per share, with a total value of $321,750.00.
- On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.12 per share, with a total value of $252,000.00.
- On Tuesday, September 9th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.29 per share, for a total transaction of $129,000.00.
Standard BioTools Stock Performance
LAB stock traded up $0.01 on Friday, reaching $1.29. The company's stock had a trading volume of 282,380 shares, compared to its average volume of 1,652,264. The business has a fifty day simple moving average of $1.28 and a two-hundred day simple moving average of $1.23. The firm has a market cap of $494.17 million, a PE ratio of -4.05 and a beta of 1.25. Standard BioTools Inc. has a 12-month low of $0.92 and a 12-month high of $2.25.
Analyst Ratings Changes
Several brokerages have recently weighed in on LAB. TD Cowen reduced their price target on Standard BioTools from $1.55 to $1.35 and set a "hold" rating for the company in a report on Wednesday, November 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Wall Street Zen cut Standard BioTools from a "hold" rating to a "strong sell" rating in a research report on Saturday, November 8th. Finally, Cowen lowered shares of Standard BioTools from a "buy" rating to a "hold" rating in a report on Wednesday, August 13th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and an average target price of $1.35.
Check Out Our Latest Research Report on LAB
Institutional Trading of Standard BioTools
Several hedge funds have recently bought and sold shares of LAB. Jump Financial LLC bought a new position in Standard BioTools during the first quarter valued at approximately $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in Standard BioTools by 115.6% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock worth $29,000 after acquiring an additional 14,541 shares in the last quarter. CWM LLC lifted its stake in shares of Standard BioTools by 101.8% in the 1st quarter. CWM LLC now owns 29,705 shares of the company's stock valued at $32,000 after purchasing an additional 14,984 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Standard BioTools by 2,989.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company's stock valued at $33,000 after purchasing an additional 24,211 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Standard BioTools by 50.3% in the second quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company's stock worth $36,000 after buying an additional 9,986 shares during the last quarter. Hedge funds and other institutional investors own 53.74% of the company's stock.
About Standard BioTools
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
